Camurus announces outcome of the arbitration process with Braeburn

Lund, Sweden — 10 December 2020 — Camurus AB (NASDAQ STO: CAMX) today announces that the ICC International Court of Arbitration has issued a partial award in the arbitration process between Camurus and Braeburn regarding the parties’ license agreement for the development and commercialization of CAM2038 in North America. The arbitral tribunal decided that Braeburn was not in material breach of the parties’ license agreement at the time of Camurus’ notice of breach on 16 April 2020. The ruling means that the license agreement between the parties remains in full force and effect. The allocation of legal costs of the arbitration is yet to be decided by the tribunal.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com.  

This is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 5:45 pm CET on 10 December 2020.